WCLC: AstraZeneca's detailed Imfinzi, tremelimumab data in metastatic NSCLC are far from a clear-cut win

After two high-profile late-stage trial flops, AstraZeneca has finally scored a victory for Imfinzi and ill-fated tremelimumab in newly diagnosed metastatic non-small cell lung cancer (NSCLC). But in a lucrative field where immuno-oncology rivals Merck and Bristol Myers Squibb have established a solid presence, a detailed look at the data reveals a win that’s perhaps too little, too late.